TipRanks
Immunic (IMUX)
NASDAQ:IMUX
US Market
IMUX
Immunic
RESEARCH TOOLSreports
Want to see IMUX full AI Analyst Report?

Immunic (IMUX) Stock Forecast & Price Target

2,265 Followers
See the Price Targets and Ratings of:

IMUX Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Immunic
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IMUX Stock 12 Month Forecast

Average Price Target

$37.38
▲(126.65% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Immunic in the last 3 months. The average price target is $37.38 with a high forecast of $70.00 and a low forecast of $22.00. The average price target represents a 126.65% change from the last price of $16.49.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","71":"$71","20.75":"$20.8","37.5":"$37.5","54.25":"$54.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,20.75,37.5,54.25,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.64,13.36,18.08,22.8,27.52,32.239999999999995,36.96,41.68,46.4,51.12,55.839999999999996,60.559999999999995,65.28,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.64,10.850384615384616,13.060769230769232,15.271153846153846,17.481538461538463,19.691923076923075,21.90230769230769,24.112692307692306,26.323076923076922,28.533461538461538,30.743846153846153,32.95423076923077,35.16461538461538,{"y":37.375,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.64,9.667692307692308,10.695384615384615,11.723076923076924,12.750769230769231,13.778461538461539,14.806153846153848,15.833846153846155,16.861538461538462,17.88923076923077,18.916923076923077,19.944615384615386,20.972307692307695,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.599,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.788,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.337,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.539,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.599,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.65,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.13,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.81,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.97,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.58,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.64,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$70.00Average Price Target$37.38Lowest Price Target$22.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on IMUX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$25
Buy
51.61%
Upside
Reiterated
10/08/26
Stifel Nicolaus Remains a Buy on Immunic (IMUX)
LifeSci Capital Analyst forecast on IMUX
Sam Slutsky
LifeSci Capital
LifeSci Capital
$56
Buy
239.60%
Upside
Reiterated
09/11/26
Unchanged $56 Target as Slutsky Reiterates Buy on IMUX, Highlighting Vidofludimus Calcium’s Dual Mechanism and Safety Advantage in MS
Leerink Partners Analyst forecast on IMUX
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$12.19→
Buy
―
Reiterated
09/10/26
Leerink Partners Sticks to Its Buy Rating for Immunic (IMUX)
William Blair Analyst forecast on IMUX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
09/10/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX) and UnitedHealth (NYSE: UNH)
Wedbush Analyst forecast on IMUX
Martin Fan
Wedbush
Wedbush
$45
Buy
172.89%
Upside
Reiterated
09/10/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on IMUX
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
$22
Buy
33.41%
Upside
Reiterated
09/10/26
Analysts Are Bullish on These Healthcare Stocks: Immunic (IMUX), Celldex (CLDX)
B. Riley Securities Analyst forecast on IMUX
William Wood
B. Riley Securities
B. Riley Securities
$27
Buy
63.74%
Upside
Reiterated
09/02/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fortrea Holdings Inc. (NASDAQ: FTRE), Medtronic (NYSE: MDT) and Immunic (NASDAQ: IMUX)
Roth MKM Analyst forecast on IMUX
Boobalan Pachaiyappan
Roth MKM
Roth MKM
$19→$29
Buy
75.86%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX), Incyte (NASDAQ: INCY) and Eli Lilly & Co (NYSE: LLY)
Guggenheim Analyst forecast on IMUX
Yatin Suneja
Guggenheim
Guggenheim
$70
Buy
324.50%
Upside
Reiterated
08/11/26
Immunic (IMUX) Gets a Buy from Guggenheim
Wolfe Research Analyst forecast on IMUX
Rudy Li
Wolfe Research
Wolfe Research
$25
Buy
51.61%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (NASDAQ: KRYS) and Immunic (NASDAQ: IMUX)
D. Boral Capital Analyst forecast on IMUX
Jason Kolbert
D. Boral Capital
D. Boral Capital
―
Hold
―
Downgraded
04/15/26
Immunic downgraded to Hold from Buy at D. Boral CapitalImmunic downgraded to Hold from Buy at D. Boral Capital
Ladenburg Thalmann & Co. Analyst forecast on IMUX
Aydin Huseynov
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$30
Buy
81.93%
Upside
Initiated
10/16/25
Immunic initiated with a Buy at LadenburgImmunic initiated with a Buy at Ladenburg
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on IMUX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$25
Buy
51.61%
Upside
Reiterated
10/08/26
Stifel Nicolaus Remains a Buy on Immunic (IMUX)
LifeSci Capital Analyst forecast on IMUX
Sam Slutsky
LifeSci Capital
LifeSci Capital
$56
Buy
239.60%
Upside
Reiterated
09/11/26
Unchanged $56 Target as Slutsky Reiterates Buy on IMUX, Highlighting Vidofludimus Calcium’s Dual Mechanism and Safety Advantage in MS
Leerink Partners Analyst forecast on IMUX
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$12.19→
Buy
―
Reiterated
09/10/26
Leerink Partners Sticks to Its Buy Rating for Immunic (IMUX)
William Blair Analyst forecast on IMUX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
09/10/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX) and UnitedHealth (NYSE: UNH)
Wedbush Analyst forecast on IMUX
Martin Fan
Wedbush
Wedbush
$45
Buy
172.89%
Upside
Reiterated
09/10/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on IMUX
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
$22
Buy
33.41%
Upside
Reiterated
09/10/26
Analysts Are Bullish on These Healthcare Stocks: Immunic (IMUX), Celldex (CLDX)
B. Riley Securities Analyst forecast on IMUX
William Wood
B. Riley Securities
B. Riley Securities
$27
Buy
63.74%
Upside
Reiterated
09/02/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fortrea Holdings Inc. (NASDAQ: FTRE), Medtronic (NYSE: MDT) and Immunic (NASDAQ: IMUX)
Roth MKM Analyst forecast on IMUX
Boobalan Pachaiyappan
Roth MKM
Roth MKM
$19→$29
Buy
75.86%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX), Incyte (NASDAQ: INCY) and Eli Lilly & Co (NYSE: LLY)
Guggenheim Analyst forecast on IMUX
Yatin Suneja
Guggenheim
Guggenheim
$70
Buy
324.50%
Upside
Reiterated
08/11/26
Immunic (IMUX) Gets a Buy from Guggenheim
Wolfe Research Analyst forecast on IMUX
Rudy Li
Wolfe Research
Wolfe Research
$25
Buy
51.61%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (NASDAQ: KRYS) and Immunic (NASDAQ: IMUX)
D. Boral Capital Analyst forecast on IMUX
Jason Kolbert
D. Boral Capital
D. Boral Capital
―
Hold
―
Downgraded
04/15/26
Immunic downgraded to Hold from Buy at D. Boral CapitalImmunic downgraded to Hold from Buy at D. Boral Capital
Ladenburg Thalmann & Co. Analyst forecast on IMUX
Aydin Huseynov
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$30
Buy
81.93%
Upside
Initiated
10/16/25
Immunic initiated with a Buy at LadenburgImmunic initiated with a Buy at Ladenburg
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
MDWDMediwound
OVIDOvid Therapeutics
IMUXImmunic
ASNDAscendis Pharma
AORTArtivion
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunic

3 Months
Myles MinterWilliam Blair
Success Rate
7/13 ratings generated profit
54%
Average Return
+19.28%
Copying Myles Minter's trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +19.28% per trade.
1 Year
Myles MinterWilliam Blair
Success Rate
7/13 ratings generated profit
54%
Average Return
+0.18%
Copying Myles Minter's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +0.18% per trade.
2 Years
Myles MinterWilliam Blair
Success Rate
4/13 ratings generated profit
31%
Average Return
-13.21%
Copying Myles Minter's trades and holding each position for 2 Years would result in 30.77% of your transactions generating a profit, with an average return of -13.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMUX Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
13
11
5
10
11
Buy
2
1
2
4
4
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
12
7
14
15
In the current month, IMUX has received 15 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IMUX average Analyst price target in the past 3 months is 37.38.
Each month's total comprises the sum of three months' worth of ratings.

IMUX Financial Forecast

IMUX Earnings Forecast

Next quarter’s earnings estimate for IMUX is -$0.94 with a range of -$2.58 to -$0.60. The previous quarter’s EPS was -$0.80. IMUX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IMUX has Performed in-line its overall industry.
Next quarter’s earnings estimate for IMUX is -$0.94 with a range of -$2.58 to -$0.60. The previous quarter’s EPS was -$0.80. IMUX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IMUX has Performed in-line its overall industry.
No data currently available

IMUX Sales Forecast

Next quarter’s sales forecast for IMUX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IMUX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IMUX has Performed in-line its overall industry.
Next quarter’s sales forecast for IMUX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IMUX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IMUX has Performed in-line its overall industry.

IMUX Stock Forecast FAQ

What is IMUX’s average 12-month price target, according to analysts?
Based on analyst ratings, Immunic’s 12-month average price target is 37.38.
    What is IMUX’s upside potential, based on the analysts’ average price target?
    Immunic has 126.65% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IMUX a Buy, Sell or Hold?
          Immunic has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Immunic’s price target?
            The average price target for Immunic is 37.38. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $70.00 ,the lowest forecast is $22.00. The average price target represents 126.65% Increase from the current price of $16.49.
              What do analysts say about Immunic?
              Immunic’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of IMUX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.